<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00450307</url>
  </required_header>
  <id_info>
    <org_study_id>05-015</org_study_id>
    <secondary_id>MSKCC-05015</secondary_id>
    <nct_id>NCT00450307</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma</brief_title>
  <official_title>3F8 Antibody Dose Escalation Plus Granulocyte-Macrophage Colony-Stimulating Factor in High-Risk Neuroblastoma: A Phase I Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as 3F8, can block tumor growth in different ways. Some&#xD;
      block the ability of tumor cells to grow and spread. Others find tumor cells and help kill&#xD;
      them or carry tumor-killing substances to them. Colony-stimulating factors, such as GM-CSF,&#xD;
      may increase the number of immune cells found in bone marrow or peripheral blood. Giving&#xD;
      monoclonal antibody therapy together with GM-CSF may be an effective treatment for&#xD;
      neuroblastoma.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of monoclonal antibody&#xD;
      3F8 when given together with GM-CSF in treating young patients with high-risk, refractory or&#xD;
      relapsed neuroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of monoclonal antibody 3F8 when administered with&#xD;
           sargramostim (GM-CSF) in young patients with high-risk, refractory or relapsed&#xD;
           neuroblastoma.&#xD;
&#xD;
        -  Assess anti-neuroblastoma effects of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study of monoclonal antibody 3F8.&#xD;
&#xD;
      Patients receive sargramostim (GM-CSF) subcutaneously once daily on days -5 to 11 and&#xD;
      monoclonal antibody 3F8 IV over 30 minutes on days 0-4 and 7-11. Treatment repeats every 4-6&#xD;
      weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of monoclonal antibody 3F8 until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of monoclonal antibody 3F8</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-neuroblastoma effects of monoclonal antibody 3F8 and sargramostim (GM-CSF)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>3F8 and GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One cycle has 5 days of 3F8 treatment. Each day, patients receive GM-CSF subcutaneously ~1.5 hr before the start 3F8 infusion. To limit side-effects, patients receive analgesics, antihistamines, and a small dose (IV, over ~5 minutes) of heat-modified 3F8. Cycles can be repeated after a 2-4 week interval, up to a total of two cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>monoclonal antibody 3F8</intervention_name>
    <arm_group_label>3F8 and GM-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <arm_group_label>3F8 and GM-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a diagnosis of NB as defined by international criteria,45 i.e.,&#xD;
             histopathology (confirmed by the MSKCC Department of Pathology) or BM metastases plus&#xD;
             high urine catecholamine levels.&#xD;
&#xD;
          -  Patients must have refractory or relapsed high-risk NB (including MYCNamplified stage&#xD;
             3/4/4S and MYCN-nonamplified stage 4 &gt;18 months old) resistant to standard therapy.&#xD;
&#xD;
          -  Prior treatment with 3F8 is allowed.&#xD;
&#xD;
          -  Age &lt;21 years.&#xD;
&#xD;
          -  Signed informed consent indicating awareness of the investigational nature of this&#xD;
             program.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Existing major organ dysfunction should be grade 2 or less, with the exception of&#xD;
             myelosuppression (neutrophil count &gt;500/ul and platelet count &gt;10,000/ul are&#xD;
             acceptable), alopecia, hearing loss. Patient cannot be taking antihypertensive&#xD;
             medication.&#xD;
&#xD;
          -  History of allergy to mouse proteins.&#xD;
&#xD;
          -  Active life-threatening infection.&#xD;
&#xD;
          -  Human anti-mouse antibody (HAMA) titer &gt;1000 ELISA units/ml.&#xD;
&#xD;
          -  Prior treatment with 3F8 is NOT an exclusion criterion.&#xD;
&#xD;
          -  Inability to comply with protocol requirements.&#xD;
&#xD;
          -  Pregnant women are excluded for fear of danger to the fetus. Therefore negative&#xD;
             pregnancy test is required for all women of child-bearing age, and appropriate&#xD;
             contraception is used during the study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian H. Kushner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kushner BH, Kramer K, Modak S, Cheung NK. Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study. J Clin Oncol. 2011 Mar 20;29(9):1168-74. doi: 10.1200/JCO.2010.28.3317. Epub 2011 Feb 22.</citation>
    <PMID>21343563</PMID>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>March 20, 2007</study_first_submitted>
  <study_first_submitted_qc>March 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2007</study_first_posted>
  <last_update_submitted>October 14, 2013</last_update_submitted>
  <last_update_submitted_qc>October 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>localized unresectable neuroblastoma</keyword>
  <keyword>regional neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

